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Background: Hypoventilation due to respiratory muscle atrophy is the most common cause of death as a result of
amyotrophic lateral sclerosis (ALS). Patients aged over 65 years and presenting bulbar symptoms are likely to have a
poorer prognosis. The aim of the study was to assess the possible impact of age and treatment with non-invasive
ventilation (NIV) on survival in ALS. Based on evidence from earlier studies, it was hypothesized that NIV increases
rates of survival regardless of age.
Methods: Eighty-four patients diagnosed with ALS were followed up on from January 2001 to June 2012. These
patients were retrospectively divided into two groups according to their age at the time of diagnosis: Group 1
comprised patients aged ≤ 65 years while Group 2 comprised those aged > 65 years. Each group included 42
patients. NIV was tolerated by 23 patients in Group 1 and 18 patients in Group 2. Survival was measured in months
from the date of diagnosis.
Results: The median age in Group 1 was 59 years (range 49 – 65) and 76 years in Group 2 (range 66 – 85).
Among patients in Group 1 there was no difference in probability of survival between the NIV users and non-users
(Hazard Ratio = 0.88, 95% CI 0.44 – 1.77, p = 0.7). NIV users in Group 2 survived longer than those following
conventional treatment (Hazard Ratio = 0.25, CI 95% 0.11 – 0.55, p <0.001). ALS patients in Group 2 who did not use
NIV had a 4-fold higher risk for death compared with NIV users.
Conclusions: This retrospective study found that NIV use was associated with improved survival outcomes in ALS
patients older than 65 years. Further studies in larger patient populations are warranted to determine which factors
modify survival outcomes in ALS.
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Amyotrophic lateral sclerosis (ALS) is a neuromuscular
disease characterized by progressive muscular atrophy
throughout the body. Hypoventilation due to respiratory
muscle atrophy is the most common cause of death in
advanced ALS cases [1,2]. The presence of bulbar symp-
toms at the time of diagnosis and advanced age
(>65 years) have been associated with poorer survival
outcomes [3]. No curative treatment is currently avail-
able and intervention is always palliative [4-7]. Riluzole,* Correspondence: tuwasi@utu.fi
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reproduction in any medium, provided the ora tedrotoxin-sensitive sodium channel blocker, is the
only existing treatment and can delay disease progres-
sion with few months [8,9].
Non-invasive ventilation (NIV) can relieve dyspnoea,
increase quality of life, and improve survival outcomes;
particularly among ALS patients without severe bulbar
symptoms [10-13]. Several guidelines currently recom-
mend the use of NIV as palliative treatment for ALS [4-7].
The effect of age has not been addressed in previous stu-
dies assessing the impact of NIV on survival outcomes
[10,12,13]. Therefore, the effect of NIV on survival was
compared in patients aged 65 years and older of age at the
time of diagnosis, designated as Group 1 and Group 2
respectively. Based on previous studies [10,12,13] it wastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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survival outcomes in both age groups when compared
with patients who declined NIV were unable to tolerate
treatment.Methods
Design
A registry-based retrospective cohort study was under-
taken, covering the period January 2001 to June 2012, on
91 patients fulfilling the El Escorial World Federation
criteria for probable or definitive ALS [14]. Once a posi-
tive diagnosis was made by a neurologist, patients were
referred to a specialist to evaluate their suitability for
NIV. All patients were systematically followed up at
intervals of 3 to 6 months, until the date of death or
June 1 2012, when the follow-up period ended. NIV and
other palliative treatments were offered to all the pa-
tients. Six patients showed survival over ten years and
this finding was quite consistent with earlier studies
which have been shown that 5 to 10% of ALS patients
will survive over ten years [15]. Two of these six patients
(age 54 and 79 years) used NIV while the rest of the
patients (age range 49 – 63 years) refused NIV. Because
of possible bias resulting from small number of patients
with slow disease progression, these cases were ex-
cluded. In addition, one patient was excluded because of
commencement of NIV before the time of diagnosis for
treatment of respiratory insufficiency due to pulmonary
embolism. Because of current clinical trials legislation in
Finland, patient consent is not required for register stu-
dies. Patient consent was therefore not obtained in this















Figure 1 Flowchart of the study.Committee of the Hospital District of South-West
Finland.
Altogether, 84 patients were included and retrospec-
tively divided into two groups based on their age at the
time of the diagnosis: Group 1 (age ≤ 65 years) and
Group 2 (age > 65 years). Both groups were then sub-
divided further based on patients´ ability to tolerate the
NIV. These were designated as the NIV Group and the
Conventional Group, as presented in Figure 1.
Patients’ age, gender, self-reported time from first
neurological symptoms to diagnosis (months), use of
percutaneous endoscopic gastrostomy (PEG), use of
NIV, use of riluzole and survival time from diagnosis
were recorded. The presence of any cardiovascular co-
morbidity was adjusted for, because it may have modi-
fied survival outcomes. This was operationalized as a
binary variable. A dichotomous variable was generated
to categorize cases according to their initial symptoms
and disease history, which were classified as either
bulbar onset (difficulties in facial function or swallowing
as an initial symptom) or spinal onset (voluntary muscle
fatigue as initial symptoms). Patients presenting with
both bulbar and spinal symptoms were classified as
bulbar onset cases.
Ventilatory support
All patients received information regarding hypoven-
tilation treatment and the possibility of participating in
the NIV trial. When hypoventilation occurred, suitability
for NIV was assessed by a pulmonologist and an anaes-
thesiologist. The primary criteria for recommending for
NIV were an increase in the partial pressure of carbon
dioxide (pCO2) to over 5.5 kPa, or a decrease in the001 – 2012
Group 2






Slow progression > 10 years n = 6







Table 1 Patients characteristics
Group 1 (age ≤ 65 years) Group 2 (age > 65 years)
NIV (n = 23) Conventional
(n = 19)
p value Number of total NIV (n = 18) Conventional
(n = 24)
p value Number of total
Male / Female 10 / 13 10 / 9 0.6 20 / 22 9 / 9 8 / 16 0.3 17 / 25
Bulbar onset, number of patients (%) 9 (39%) 10 (53%) 0.4 19 / 42 5 (28%) 13 (54%) 0.1 18 / 42
Use of PEG, number of patients (%) 13 (57%) 10 (53%) 0.8 23 / 42 8 (44%) 10 (42%) 0.9 18 / 42
Use of riluzole, number of patients (%) 10 (43%) 11 (58%) 0.4 21 / 42 7 (39%) 5 (21%) 0.2 12 / 42
Hypertension or other cardiovascular diseases, number of patients (%) 8 (35%) 3 (16%) 0.3* 11 / 42 12 (67%) 11 (46%) 0.2 23 / 42
Median time from onset of symptoms until diagnosis, months (range) 12 (2 – 36) 10 (3 – 24) 0.5** 12 (7 – 60) 12 (1 – 54) 0.8**
Median age at diagnosis, years (range) 61 (49 – 65) 58 (49 – 65) 0.3** 76 (66 – 85) 77 (66 – 84) 0.7**
NIV = non-invasive ventilation, Conventional = no assisted ventilation, PEG = percutaneous endoscopic gastrostomy. The differences between the two groups were assessed using the Chi square test, except for number
of patients having hypertension or other cardiovascular diseases, which was assessed with Fisher’s exact test*. The values for median age at diagnosis and time from onset of symptoms until diagnosis were compared


















Figure 2 Kaplan-Meier survival curves for patients with and
without non-invasive ventilation in two age groups. Curve
comparisons were analyzed using the log rank test.
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sured by a morning arterial blood gas sample. Additional
measurements included dyspnoea at rest, forced vital
capacity (FVC), peak cough flow (PCF), maximum in-
spiratory mouth pressure (MIP), maximum expiratory
mouth pressure (MEP), and sniff nasal pressure (SNP);
all of which are considered secondary criteria for NIV
diagnosis. These additional measurements were not
always taken at the time of NIV initiation. Therefore,
only pCO2 and pO2 measurements were reported, which
were available for all patients. The final decision was
based on each patient’s willingness to undergo NIV
treatment, regardless of observed dyspnoea or an eleva-
ted morning pCO2.
NIV was given using a pressure-assisted ventilator
(VPAP III ST®, ResMed, Bella Vista, Australia). The aver-
age weekly duration of NIV use was collected using the
device’s in-built counter, normally at 3-month intervals.
Patients undergoing NIV less than 4 hours per day at
the last control visit, timed one week to 3 months prior
to death, were considered NIV-intolerant and were allo-
cated to the Conventional Group.
Statistical analyses
The results are given as mean with 95% confidence
intervals if not otherwise stated. Chi-square tests were
used to compare discrete variables between the groups.
Time (in months) from the onset of the symptoms until
diagnosis was analysed using a Mann–Whitney U test.
Comparison of the mean arterial pCO2 and pO2 at the
moment of NIV initiation and the mean daily use of
NIV was performed using a Student’s t-test. Survival
time was measured in months from diagnosis until death
or June 2012, when the follow-up ended. The interac-
tions of age and NIV use with survival were assessed
using a Cox regression. Survival curves were analysed
using the Kaplan-Meier method and the Log-Rank Test.
Proportional hazard assumptions were evaluated using
Kaplan-Meier plots, with p < 0.05 denoting statistically
significant difference. All analyses were carried out using
SAS System version 9.2 for Windows (SAS Institute Inc.,
Cary, NC).
Results
A total of 84 patients (37 male, 47 female) were included
in this study. The median age in Group 1 was 59 years
(range 49 – 65) and 76 years (66 – 85) in Group 2. NIV
was tolerated by 23 subjects in Group 1 and 18 in Group
2. There were no statistically significant differences in
any of the patient characteristics measured at baseline
(see Table 1). Mean arterial pCO2 at the time of NIV
initiation was 6.3 (SD = 1.5) kPa in the Group 1 NIV sub-
group and 6.5 kPa (SD = 1.3, p = 0.7) in the Group 2 NIV
subgroup. Mean arterial pO2 readings at the time of NIVinitiation were 10.9 kPa (SD = 2.2) and 9.7 kPa (SD = 1.5,
p = 0.1) for the Group 1 and Group 2 NIV subgroups,
respectively. The mean daily duration of NIV at the last
control visit prior to the death 17 h (SD = 7) in Group 1
and 14 h (SD = 6) (p = 0.2).
Median survival in the Group 1 NIV subgroup was
14 months (range 1 – 60) and 15 months (range 5 – 38)
in the Group 1 conventional subgroup. No significant
difference was found in survival between the NIV and
conventional treatment groups among patients in Group
1 (Hazard Ratio = 0.88, 95% CI 0.44 – 1.77, p = 0.7). In
Group 2, NIV users survived longer (median 22 months,
range 3 – 65) than those undergoing conventional (me-
dian 8 months, range 1 – 26 months) treatment (Hazard
Ratio = 0.25, 95% CI 0.11 – 0.55, p <0.001). Group 2 NIV
non-users showed a 4-fold increased risk of mortality
compared with NIV users. The Kaplan-Meier curves for
both groups are presented in Figure 2.
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This study’s retrospective analysis found that NIV use
was associated with an improved survival rate in ALS
patients older than 65 years. In an earlier study, del
Aguila et al. found that mean age of 65 years at the time
of diagnosis was an independent risk factor for adverse
outcomes [3]. In the present study the risk of mortality
among patients in Group 1 who did not receive NIV
was four-fold when compared with NIV users. Surpris-
ingly, there was no difference in survival rates among
ALS patients under 65 years with or without NIV ther-
apy. The median period from the onset of symptoms to
diagnosis was 12 months in all four groups, indicating
that there were no differences in diagnostic delay bet-
ween the groups. The study’s retrospective design did
not allow us to evaluate the impact of NIV on quality of
life. However, 14 or more hours of NIV daily is likely to
indicate compliance in both age groups.
The mechanism by which NIV may modify survival
outcomes has not been fully elucidated. It is suggested
that the survival outcomes in ALS patients are im-
proved if NIV is initiated before ventilatory function is
severely reduced (i.e. before the vital capacity is re-
duced) [12]. A prospective study conducted by Lecthzin
et al. found that while thoracic compliance is reduced
in ALS patients presenting with hypoventilation, in-
spiratory pressure support can improve compliance
[16]. Based on this finding they suggested that NIV
may provide nocturnal rest for fatigued respiratory
muscles, thereby increasing survival rates by improving
daytime functioning of respiratory muscles [12]. How-
ever, other studies considering the impact of NIV on
ALS patients were retrospective in nature [12,17] and
therefore their conclusions as to possible mechanisms
by which NIV might improve survival outcomes are
unconfirmed.
This study has some limitations. Its analysis was
performed retrospectively in a relatively small patient
population. The mechanisms by which NIV improved
survival outcomes in Group 2 are unclear. Theoretically,
improved survival may have been at least partly due to
slight but statistically insignificant difference in the
frequency of bulbar symptoms between the NIV users
and non-users. There is compelling evidence demon-
strating that survival is poorest in ALS patients with
severe bulbar symptoms [10]. Poor survival may also be
due to poor compliance with NIV therapy. This likely to
be a contributing factor also in the present study be-
cause many Group 2 patients with bulbar dysfunction
did not tolerate NIV. The results of this study should
therefore be confirmed by studying a larger patient co-
hort and, using a prospective study design. However,
because of the fact that NIV has been established as a
palliative method of choice for ALS, the ethicalconsiderations for withholding treatment should be
taken seriously into account in any future prospective
studies.
Second, all patients were referred for evaluation after a
diagnosis of ALS was confirmed. It was therefore not
possible to assess the ventilatory function of patients in
the early stage of the disease, preventing us from
assessing the possible impact of early NIV initiation on
survival outcomes. In addition, most of this study’s pa-
tients gave consent for NIV trial in at a later stage of the
disease and presented a pCO2 greater than 6.0 kPa, even
if NIV was recommended for these patients in line with
current guidelines [4-7]. It is therefore possible that this
study failed to show that the initiation of NIV would
have had a beneficial effect on the survival in younger
NIV patients because the initiation of NIV was decided
by the patient.
Factors other than NIV may also have had an effect on
patient survival. These include treatment with PEG or
riluzole, and gender. In addition, the incidence of hyper-
tension and other cardiovascular diseases, decline in pul-
monary function as well and whole body function may
have impacted patients’ survival outcomes. PEG use may
increase survival by months [18]. The same is true also
for riluzole, the efficacy of which has been demonstrated
in randomized controlled trials [8,9]. Female gender has
been found to be an independent risk factor for worse
outcomes [3]. In this study, the groups did not differ
significantly in terms of gender or access to PEG or
riluzole treatment. Patient numbers were low, however,
resulting in a lack of power to detect significant differ-
ences between groups. It was therefore not possible to
evaluate the possible effect of these factors on survival.
Further studies in larger patient populations are needed
to determine which factors affect clinical outcomes in
ALS.
Conclusion
The results of this retrospective cohort study suggest
that the effect of NIV on survival in ALS patients is age-
dependent. Use of NIV was associated with improved
survival outcomes in ALS patients older than 65 years.
However, further studies using a prospective design are
needed to confirm the present results.
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